Neuropore

Our Mission

To discover and develop novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

News

Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018

Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

See All News

Events

Neuropore Therapies (NPT^®) Researcher Dr. Agata Habas to Present Poster and Oral Presentations Entitled, "Novel TLR2 Small Molecule Antagonists Inhibit Alpha-Synuclein-Induced Pro-inflammatory Signaling and Cytokine Release" at the Gordon Research Conference, Neurobiology of Brain Disorders; August 5-10th, 2018 in Castelldefels, Spain .

Click here for more information

See All Events

NPT^® Publications

Neuropore publishes paper describing the discovery and characterization of a small molecule compound targeting α-synuclein as a potential Parkinson’s disease therapeutic October 5th, 2016

Report in Brain, describes findings supporting the hypothesis that NPT^®100-18A reduces alpha-synuclein toxicity through a novel mechanism that involves displacing pathological alpha-synuclein from the membrane.

See All Publications